CONTRIBUTION OF A FIXED-DOSE ABACAVIR/LAMIVUDINE COMBINATION TO IMPROVING TREATMENT COMPLIANCE IN HIV-INFECTED PATIENTS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The use of fixed-dose combinations of(FDC) of nucleoside reverse transcriptase inhibitors in an antiretrovirus therapy (ARVT) regimen has today certain benefits, by reducing the amount of drugs and the frequency of their administration. The review gives the results of some large studies (including cohort ones) of the efficiency and safety of ARVT regimens including the FDC of abacavir and lamivudine (Kivexa). The proportion of patients showing a high compliance (> 95%) ensuring the optimal virologic suppression was higher with FDC than that with monodrugs (39 and 31%). The results of the investigation demonstrated that the application of FDC increases adherence to not only treatment as a whole, but also that to dosage (from 91.9 to 97.1%), administration time (from 86.3 to 95.5%), a third medication in the ARVT regimen (from 85 to 92.3%), treatment satisfaction (from 85 to 92%), and first-line therapy duration. In addition, FDCs permit specialists to more effectively manage comorbidities requiring co-treatment (for opportunistic infections, tuberculosis, chronic viral hepatitides, etc.). Having a high virologic and immunologic efficacy and a favorable safety and tolerance profile, Kivexa is incorporated into first-line ARTV regimens by most current guidelines, including the Russian National Research Society of Infectiologists guidelines (2012).

Full Text

Restricted Access

About the authors

Veronika G. KANESTRI

Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare

Email: kanestri@yandex.ru
Moscow

References

  1. Parienti J.J., Ragland K., Lucht F. et al. Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication. Clin. Infect. Dis. 2010; 50: 1192-1197.
  2. Low-Beer S., Yip B., O,Shaughnessy M.V. et al. Adherence to triple therapy and viral load response. J. Acquir. Immune Defic. Syndr. 2000; 23(4): 360-361.
  3. Miller L.G, Liu H., Hays R.D. et al. Knowledge of antiretroviral regimen dosing and adherence: a longitudinal study. Clin Infect Dis. 2003; 36: 514-518.
  4. Kleeberger C.A., Phair J.P., Strathdee S.A. et al. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. J. Acquir. Immune Defic. Syndr. 2001; 26: 82-92.
  5. Ammassari A., Murri R., Pezzotti P. et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J. Acquir. Immune Defic. Syndr. 2001; 28: 445-449.
  6. Stone V.E., Jordan J., Tolson J. et al. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J. Acquir. Immune Defic. Syndr. 2004; 36: 808-816.
  7. Bangalore S., Kamalakkannan G., Parkar S. et al. Fixed-dose combinations improve medication compliance: a meta-analisis. Am. J. Med. 2007; 1206: 713-719.
  8. Claxton A.J., Cramer J., Pierce C. A systematic review of the associations between dose regimens and edication compliance. Clin. Ther. 2001; 23: 1296-1310.
  9. Parienti J.J., Bangsberg D.R., Verdon R. et al. Better adherence with once-daily antiretroviral regimens: a meta-analisis. Clin. Infect. Dis. 2009; 48: 484-488.
  10. Willing J.H., Abroms S., Westfall A.O. et al. Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS 2008; 22(15): 1951-1960.
  11. Бартлетт Д., Галлант Д., Фам П. Клинические аспекты ВИЧ-инфекции. 2009-2010. М.: Р.Валент, 2010. 490 с.
  12. GlaxoSmithKline. Kivexa package insert. Research triangle park, NC: GlaxoSmithKline, 2004.
  13. DeJesus E., Herrera G., Teofilo E. et al. For the CNA30024 study team. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin. Infect. Dis. 2004; 39: 1038-1046.
  14. Shafer M.S., Smith K.Y., Patel P. et al. (for the HEAT Study Team). Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ ritonavir for initial HIV treatment. AIDS 2009; 23(12): 1547-1556.
  15. Stellbrink H.J., Moyle G., Orkin C. et al. Assessment of safety and efficacy of abacavir/lamivudine and tenofovir/emtricitabine in treatment-naive HIV-1 infected subjects. ASSERT: 48-week result. 12th European AIDS Conference. Cologne, Germany, 2009. PS10/1.
  16. Daar E., Tierney C., Fischl M., et al. ACTG 5202: final results of ABC/3TC or TDF/FTC with either EFV or ATV/r in treatmentnaive HIV-infected patients. Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, California, 2010. Abstract 59LB.
  17. Martinez E., Arranz J.A., Podzamczer D. et al. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/ emtricitabine in HIV-1-infected patients with virological suppression (BICOMBO). J. Acquir. Immune Defic. Syndr. 2009; 51(3): 290-297.
  18. Martin A., Bloch M., Amin J. et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96-week trial (STEAL). Clin. Infect. Dis. 2009; 49: 1591-1601.
  19. Campo R., DeJesus E., Khanlou H. et al. SWIFT study: switching from lamivudine/abacavir (3TC/ABC) to emtricitabine/tenofovir DF (FTC/TDF) maintained efficacy and reduced virologic failure. 6th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy, 2011. Abstract WELBB03.
  20. Ha B., Liao Q.M., Dix L.P. et al. Virologic response and safety of the abacavir/lamivudine fixed-dose formulation as part of highly active antiretroviral therapy: analyses of six clinical studies. HIV Clin. Trials 2009; 10(2): 65-75.
  21. Sosa N., Hill-Zabala C., DeJesus E. et al. Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL). J. Acquir. Immune Defic. Syndr. 2005; 40(4): 422-427.
  22. Maitland D., Jackson A., Osorio J. et al. Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with the therapy. HIV Medicine 2008; 9: 667-672.
  23. Jordan J., Delea T., Sherrill B. et al. Impact of fixed dose combination zidovudine/lamivudine on adherence to antiretroviral therapy: a retrospective claims-based cohort study. 6th International congress on drug therapy in HIV infection. Glasgow, 2002. Abstract P97.
  24. Legorreta A., Yu A., Chernicoff H. et al. Adherence to combined lamivudine+zidovudine versus individual components: a community-based retrospective Medicaid claims analysis. AIDS Care 2005; 17(8): 938-948.
  25. Kauf T.L., Davis K.L., Earnshaw S.R. et al. Spillover adherence effects of fixed-dose combination HIV therapy. Patient Preference and Adherence 2012; 6: 155-164.
  26. Kubota M., Cohen C., Scribner A. et al. Short-term safety and tolerability of ABC/3TC administered once-daily (QD) compared with the separate components administered twice-daily (BID): Results from ESS101822 (ALOHA). The 46th ICAAC. San Francisco, 2006. Poster H-1904.
  27. Дегтярев А.А., Кытманова Л.Ю. Организация работы мультипрофессиональной команды по формированию и сохранению приверженности к ВААРТ. Метод. пособие. Магнитогорск, 2010.
  28. Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Канестри В.Г., Афонина Л.Ю. и др. Протоколы диспансерного наблюдения и лечения больных ВИЧ-инфекцией. Эпидемиол. инфекц. болезни. Актуал. вопр. 2012; 6, приложение. 28 c.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies